Want to see KEQU full AI Analyst Report?
Top Page
Kewaunee Scientific
(NASDAQ:KEQU)
Select Model
Select Model
Rating:55Neutral
Price Target:
$37.00
▼(-3.52% Downside)
Action:Reiterated
Date:06/27/26
The score is held back primarily by deteriorating cash flow quality (2026 TTM operating and free cash flow at zero) and increased leverage, despite strong margin and profitability improvement versus prior years. Technicals add near-term pressure (below key moving averages with negative MACD), while valuation provides partial support via a low P/E multiple.
Positive Factors
Margin Expansion
Gross margin expansion to roughly 28% reflects sustained improvements in pricing, product mix, and operational execution versus the mid-teens in 2022. Higher structural margins support durable profitability across project cycles and give the company margin headroom to absorb cost inflation or invest in growth initiatives.
Negative Factors
Weak Cash Conversion
Zero operating and free cash flow despite reported earnings in 2026 TTM indicates poor cash conversion and working-capital stress. Over time this constrains the company’s ability to fund operations, capex, dividends, or debt servicing without external financing, raising execution risk during slower demand periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Margin Expansion
Gross margin expansion to roughly 28% reflects sustained improvements in pricing, product mix, and operational execution versus the mid-teens in 2022. Higher structural margins support durable profitability across project cycles and give the company margin headroom to absorb cost inflation or invest in growth initiatives.
Read all positive factors
Kewaunee Scientific Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where Kewaunee Scientific is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where Kewaunee Scientific is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyKewaunee Scientific (KEQU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$106.75M
Dividend YieldN/A
Average Volume (3M)8.77K
Price to Earnings (P/E)10.8
Beta (1Y)0.90
Revenue Growth17.27%
EPS Growth-15.71%
CountryUS
Employees1,231
SectorConsumer Cyclical
Sector Strength84
IndustryFurnishings, Fixtures & Appliances
Share Statistics
EPS (TTM)3.35
Shares Outstanding2,868,511
10 Day Avg. Volume10,539
30 Day Avg. Volume8,774
Financial Highlights & Ratios
PEG Ratio-0.71
Price to Book (P/B)1.42
Price to Sales (P/S)0.38
P/FCF Ratio7.21
Enterprise Value/Market Cap1.22
Enterprise Value/Revenue0.46
Enterprise Value/Gross Profit1.62
Enterprise Value/Ebitda5.44
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kewaunee Scientific Business Overview & Revenue Model
Company Description
Kewaunee Scientific Corporation, established in 1906 and based in Statesville, North Carolina, specializes in providing custom furniture and infrastructure systems for scientific, medical, and technical settings. The company manages its operations...
How the Company Makes Money
Kewaunee Scientific primarily makes money by selling laboratory furniture and ventilation-related lab products, along with associated project and installation services, to customers building new labs or renovating existing facilities. Revenue is g...
Kewaunee Scientific Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
63
Positive
Cash Flow
28
Negative
| Breakdown | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 282.00M | 240.47M | 203.75M | 219.49M | 168.87M |
| Gross Profit | 80.44M | 68.86M | 52.05M | 35.59M | 24.22M |
| EBITDA | 23.88M | 22.76M | 18.04M | 8.16M | 916.00K |
| Net Income | 9.62M | 11.40M | 18.75M | 1.36M | -6.00M |
Balance Sheet | |||||
| Total Assets | 178.31M | 194.65M | 134.77M | 118.90M | 118.77M |
| Cash, Cash Equivalents and Short-Term Investments | 11.62M | 14.94M | 23.27M | 8.08M | 4.43M |
| Total Debt | 30.18M | 50.16M | 11.00M | 12.92M | 67.56M |
| Total Liabilities | 101.50M | 128.41M | 78.56M | 80.41M | 82.59M |
| Stockholders Equity | 74.72M | 64.46M | 54.76M | 37.41M | 35.69M |
Cash Flow | |||||
| Free Cash Flow | 14.70M | 12.62M | 15.19M | -7.94M | -9.79M |
| Operating Cash Flow | 18.63M | 14.78M | 19.56M | -3.79M | -7.88M |
| Investing Cash Flow | -3.94M | -30.90M | -4.37M | -4.15M | -1.91M |
| Financing Cash Flow | -19.33M | 7.41M | -3.01M | 14.93M | 11.03M |
Kewaunee Scientific Technical Analysis
Negative
38.35
Price Trends
37.54
Negative
37.34
Negative
38.81
Negative
Market Momentum
-0.27
Negative
47.71
Neutral
56.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KEQU, the sentiment is Negative. The current price of 38.35 is above the 20-day moving average (MA) of 36.32, above the 50-day MA of 37.54, and below the 200-day MA of 38.81, indicating a bearish trend. The MACD of -0.27 indicates Negative momentum. The RSI at 47.71 is Neutral, neither overbought nor oversold. The STOCH value of 56.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KEQU.
Kewaunee Scientific Risk Analysis
Kewaunee Scientific disclosed 28 risk factors in its most recent earnings report. Kewaunee Scientific reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kewaunee Scientific Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $382.92M | 12.22 | 17.68% | 1.77% | 4.83% | 111.79% | |
69 Neutral | $563.13M | 14.07 | 8.46% | 7.86% | -4.79% | -30.21% | |
64 Neutral | $160.70M | -6.67 | -13.04% | 7.20% | -25.67% | -96.05% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
56 Neutral | $186.02M | 33.97 | 3.24% | 4.59% | 1.96% | 122.75% | |
55 Neutral | $106.75M | 10.84 | 16.29% | ― | 17.27% | -15.71% | |
53 Neutral | $96.89M | -111.65 | -0.86% | 1.59% | -22.38% | -104.75% |
* Consumer Cyclical Sector Average
KEQU
Kewaunee Scientific
36.31
-21.29
-36.96%
BSET
Bassett Furniture
21.49
3.81
21.56%
ETD
Ethan Allen
22.23
-4.24
-16.02%
FLXS
Flexsteel
71.63
34.74
94.17%
HOFT
Hooker Furniture
14.35
4.11
40.08%
VIRC
Virco Manufacturing
6.04
-1.63
-21.27%
Kewaunee Scientific Corporate Events
Financial Disclosures
Kewaunee Scientific Schedules Fiscal 2026 Earnings Release
Neutral
Jun 10, 2026
Kewaunee Scientific Corporation, a long-established global supplier of laboratory, healthcare, and technical furniture, offers a broad range of products from casework and fume hoods to biological safety cabinets and work surfaces. With manufacturi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.